There are currently 2672 clinical trials in Boston, Massachusetts looking for participants to engage in research studies. Trials are conducted at various facilities, including Massachusetts General Hospital, Dana Farber Cancer Institute, Beth Israel Deaconess Medical Center and Brigham and Women's Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
Recruiting
A phase 1/2, open-label, safety and dosing study of autologous CART cells (desmoglein 3 chimeric autoantibody receptor T cells \[DSG3-CAART\] or CD19-specific Chimeric Antigen Receptor T cells \[CABA-201\]) in subjects with active, pemphigus vulgaris
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Pemphigus Vulgaris
BCL2i CLAG-M in R/R Acute Myeloid Leukemia
Recruiting
This multicenter, open-label phase II study combines CLAG-based therapy with or without venetoclax in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) in order to improve measurable residual disease (MRD) clearance and event-free survival. Investigators hypothesize that the addition of venetoclax to CLAG-M in patients with relapsed or refractory AML is safe, and superior to CLAG-M alone in improving patient outcomes.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/14/2025
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Relapsed or Refractory Acute Myeloid Leukemia (AML)
Safety and Efficacy of NMD670 in Adult Patients with Type 1 and Type 2 Charcot-Marie-Tooth Disease
Recruiting
This Phase 2a study aims to evaluate the efficacy, safety and tolerability of NMD670 vs placebo administered twice a day (BID) for 21 days in ambulatory adult patients with Charcot-Marie-Tooth disease type 1 and type.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/14/2025
Locations: Mass General Neurology, Boston, Massachusetts
Conditions: Charcot-Marie-Tooth Disease
Exercise Training in Transthyretin Cardiac Amyloidosis
Recruiting
Transthyretin cardiac amyloidosis causes debilitating heart failure in older adults. The proposed research will develop a personalized exercise training program to improve functional capacity in patients on optimal treatment for transthyretin cardiac amyloidosis. This is a vital next step to improve functional capacity and quality of life of people suffering from transthyretin cardiac amyloidosis.
Gender:
ALL
Ages:
Between 60 years and 90 years
Trial Updated:
03/14/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Amyloid Cardiomyopathy, Transthyretin Cardiac Amyloidosis
The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant
Recruiting
This study is a phase 2 / 3 prospective, double-blind, randomized, multicenter, placebo-controlled study for prevention of acute GVHD (aGVHD) in participants undergoing an unrelated (matched or single allele mismatched) or matched related allogeneic hematopoietic cell transplantation (HCT).
Gender:
ALL
Ages:
12 years and above
Trial Updated:
03/14/2025
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Acute-graft-versus-host Disease
Effect of CPAP on 6-Minute Walk Test Outcomes in Patients with ECAC
Recruiting
The purpose of this protocol is to perform a prospective, randomized, double-blinded, pacebo-controlled clinical trial to determine the influence of a non-invasive positive pressure ventilation device on exercise capacity and symptoms in adult patients with ECAC. Primary outcome will include the total distance traversed by the study subject during a standard 6-minute walk test, and secondary outcomes will include peak flow measurement and symptom reporting before and after the exercise testing.... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Tracheobronchomalacia, Excessive Dynamic Airway Collapse
Combined Anabolic Therapy
Recruiting
In this research study the study investigators want to learn more about the effect of two different FDA-approved medication regimens in the treatment of postmenopausal osteoporosis.
Gender:
FEMALE
Ages:
45 years and above
Trial Updated:
03/13/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Osteoporosis, Postmenopausal, Osteoporosis
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease
Recruiting
The main objective of the study is to evaluate the efficacy of satralizumab compared with placebo based on time from randomization to the first occurrence of an adjudicated MOGAD relapse in the double-blind (DB) treatment period
Gender:
ALL
Ages:
12 years and above
Trial Updated:
03/13/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
Training in Evidence-based Treatments in Psycho-Oncology
Recruiting
The goal of this research study is to train psychotherapists to administer individualized evidence-based psychotherapies in a cancer care setting to participants with elevated levels of distress due to their illness and/or treatment. The intervention will mirror clinical care in psycho-oncology in which the therapist, collaboratively with their supervisor, will choose specific components of the following evidence-based treatments to administer based on the clinical presentation of the patient a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/13/2025
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Distress, Emotional, Depression, Anxiety, Fatigue, Pain, Insomnia
DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain MetAstaSEs
Recruiting
The purpose of this study is to test the safety and effectiveness of the study drug datopotamab deruxtecan in participants with metastatic breast cancer that has spread to the brain. The name of the study drug used in this research study is: Datopotamab deruxtecan (a type of antibody-drug conjugate)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/13/2025
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Breast Cancer, Breast Cancer Female, Metastatic Triple-Negative Breast Carcinoma, ER Positive Breast Cancer, HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma, ER-negative Breast Cancer
Initial Assessment of the Feasibility and Efficacy of a Scalable Digital CBT for Generalized Anxiety and Associated Health Behaviors in a Cardiovascular Disease Population
Recruiting
The treatment of generalized anxiety disorder (GAD) in an accessible manner represents an unmet need for those with cardiovascular disease (CVD), given that patients with CVD experience numerous barriers for in-person treatment engagement. The research plan for the proposed pilot project will entail: (1) open study of the acceptability of the digital intervention (N=5), followed by (2) recruitment and randomization of 90 individuals with a history of acute CVD events and clinical levels of GAD s... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/13/2025
Locations: Boston University, Boston, Massachusetts
Conditions: Anxiety Disorders, Cardiovascular Diseases, Anxiety, Health Behavior
A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema
Recruiting
The goal of this trial is to enable the collection of information about long-term safety and clinical activity of STAR-0215 in participants with hereditary angioedema (HAE). Participants will receive repeat doses of STAR-0215 for up to 5 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/13/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Hereditary Angioedema